Key Highlights

  • Third-quarter net loss reached USD 32.0 million, or USD 0.40 per ordinary share, compared with USD 3.1 million, or USD 2.36, a year earlier.
  • Research spending jumped from USD 1.4 million to USD 25.5 million, and administrative spending climbed from USD 1.7 million to USD 11.4 million.
  • Cash and marketable securities of USD 528.5 million at September 30, 2026 are projected by management to support operations through the second half of 2029.
  • The Paragon license agreement, signed November 3, 2026, covers DMR-001 and DMR-002 and carries milestone payments up to USD 22.0 million for each licensed product.

Clinical-Stage Spending Replaces a Near-Dormant Prior Year

Damora Therapeutics (NASDAQ:DMRA) submitted its quarterly filing on November 4, 2026. As a clinical-stage biotech, it develops antibodies aimed at mutant calreticulin, a protein implicated in blood disorders including essential thrombocythemia and myelofibrosis, and it has generated no product sales. Operating outlays reached USD 36.9 million, offset in part by USD 4.9 million of other income, chiefly USD 4.2 million of interest earned on cash and a USD 0.8 million gain from selling intellectual property. For nine months the net loss was USD 90.9 million, or USD 1.19 per share, versus USD 9.1 million, or USD 6.88, meaning the year-earlier figures reflect a far smaller business. Ordinary shares outstanding were 61,904,742 as of November 2, 2026.

Breakdown of Research Costs and Paragon License Terms

R&D rose USD 24.1 million, with USD 7.5 million going to preclinical and clinical work, USD 7.5 million to Manufacturing and controls, USD 4.7 million to staffing and USD 2.3 million to a Warrant obligation tied to Paramora, an affiliate of Paragon. Services supplied by Paragon accounted for USD 7.2 million of the quarter's R&D. Under the November 3, 2026 license, Damora must pay USD 2.5 million when the first patient is dosed in a Phase 1 study, along with tiered royalties in the low to mid single-digit range on net sales of monospecific antibody products. Damora has not yet exercised its option on DMR-003.

Runway, Clinical Timeline and Share Issuance Risk

Operating cash consumption for nine months came to USD 59.7 million, while investing included USD 179.5 million of marketable securities bought. In February 2026 the company sold 16,644,737 shares at USD 19.00, netting about USD 295.5 million, and it also set up an at-the-market program for up to USD 150.0 million, through which gradual sales could dilute shareholders. The Phase 1/1b CLARITY-101 study of DMR-001 began during the quarter after Australian approval and FDA clearance, and two proof-of-concept readouts are scheduled from mid-2027. A first regulatory filing for DMR-002 is aimed at the fourth quarter of 2026. The company states it will need additional funding, and a shortfall could bring going-concern doubts.

Where Things Stand

The quarterly loss is large because Damora was starting from almost nothing a year earlier, not because of a single charge. Damora Therapeutics (NASDAQ:DMRA) booked USD 32.0 million of losses but holds USD 528.5 million, which management says carries operations into the second half of 2029. Next, watch the DMR-002 filing in the fourth quarter of 2026, preclinical results at the December 2026 hematology meeting and first proof-of-concept data from mid-2027. The filing treats that runway as a management estimate that depends on assumptions which could prove wrong.